HTG MOLECULAR DIAGNOSTICS, INC
Healthcare · Laboratory Analytical Instruments · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | |
|---|---|---|---|---|---|---|
| Revenue | $6.4M | $8.9M | $8.5M | $19.2M | $21.5M | $14.8M |
| Operating income | −$20.8M | −$17.8M | −$19.6M | −$19.0M | −$16.2M | −$17.7M |
| Net income | −$21.6M | −$17.1M | −$20.9M | −$19.3M | −$16.5M | −$19.0M |
| Total assets | $17.8M | $30.5M | $35.2M | $45.1M | $43.8M | $21.3M |
| Total liabilities | $12.4M | $20.1M | $20.7M | $21.1M | $22.7M | $24.3M |
| Equity | $5.4M | $10.4M | $14.5M | $24.0M | $21.1M | −$3.1M |
| EPS (diluted) | $-24.28 | $-29.66 | — | — | — | — |
| Shares out. | 7.6M | 6.2M | 58.4M | 28.6M | 28.4M | 8.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2022- Operating margin
- −327.2%
- Net margin
- −339.2%
- Return on equity
- −400.5%
- Return on assets
- −121.5%
- Return on capital (ROCE)
- −219.1%
- Liabilities / assets
- 69.7%
- Debt / equity
- 2.30×
- Book value / share
- $0.71
- Revenue growth (YoY)
- −28.5%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2022- Altman Z″ (distress)
- -46.86distress
- Accruals / assets
- −17.9%clean
- Beneish M-Score
- -3.15normal
- Piotroski F-Score
- 2/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 4 warning● 1 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Barat StephenOfficer — Senior VP of Therapeutics | Jun 8, 2023 | Sell | 888 | $0.80 |
| Barat StephenOfficer — Senior VP of Therapeutics | Mar 31, 2023 | Tax withholding | 52 | $2.70 |
| Lawson ByronOfficer — SVP/Chief Commercial Officer | Dec 9, 2022 | Grant | 1,000 | $0.42 |
| Lubniewski John LOfficer — President & CEO | Dec 9, 2022 | Grant | 1,000 | $0.42 |
| Mcmeans Shaun DOfficer — SVP, Finance & Admin. & CFO | Dec 9, 2022 | Grant | 1,000 | $0.42 |
| Godlewski Laura LeeOfficer — SVP Finance & Administration | Dec 9, 2022 | Grant | 1,000 | $0.42 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Delisting / listing-standard noticeJun 8, 2023
- Bankruptcy or receivership · Debt acceleration / triggering event · Director / officer changeJun 5, 2023
- Delisting / listing-standard noticeMay 24, 2023
- Other material eventMay 16, 2023
- Results of operationsMay 10, 2023
- Other material eventApr 25, 2023
- Director / officer changeFeb 3, 2023
- Results of operationsJan 6, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 25-NSEJul 10, 2023
- 4FORM 4 SUBMISSIONJun 9, 2023
- 8-KJun 8, 2023
- 8-KJun 5, 2023
- 8-KMay 24, 2023
- 8-KMay 16, 2023
- 10-QMay 11, 2023
- 8-KMay 10, 2023
- 8-KApr 25, 2023
- 4FORM 4 SUBMISSIONApr 7, 2023
- 10-KMar 30, 2023
- SC 13G/AFeb 13, 2023
- 3FORM 3 SUBMISSIONFeb 10, 2023
- SC 13G/AFeb 10, 2023
- 8-KFeb 3, 2023
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.